(a) said cytostatic compound is coupled via a spacer comprising a group which is derived from a maleinimido group, to thiolated transferrin or thiolated albumin or to polyethylene glycol having at least one HS or H_2N group; or

(b) 2 to 30 equivalents of said cytostatic compound are each coupled via a spacer comprising a group which is derived from a maleinimido group, to thiolated albumin, wherein the thiolated albumin is conjugated via a group which is derived from a bismaleinimido compound to transferrin or a monoclonal antibody which is directed to a tumor associated antigen; and

wherein said thiolated transferrin or said thiolated albumin has 1 to 30 HS groups on the average, and said polyethylene glycol has a mass of about between 5,000 and 200,000 Da.

8. (New) The conjugate according to claim 7, wherein said cytostatic compound is selected from the group consisting of anthracyclines, nitrogen mustard gas derivatives, purine or pyrimidine antagonists, folic acid antagonists, taxoids, camptothecines, podophyllotoxin derivatives, vinca alkaloids and *cis*-configured platinum(II)-complexes.

9. (New) The conjugate according to claim 7, wherein said cytostatic compound is selected from the group consisting of doxorubicine, daunorubicine, epirubicine, idarubicine, mitoxandrone, chloroambucil, melphalan, 5-fluorouracil, 5'-deoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecane, 9-aminocamptothecine, etoposide, teniposide, mitopodozide, vinblastine, vincristine, vindesine, vinorelbine and compounds of the general formulas I, II, III or IV:

Formula I



Formula II



Formula III



Formula IV



wherein n = 0-6, X = $-NH_2$, -OH, -COOH, -O-CO-R-COR* or -NH-CO-R-COR*, wherein R is an aliphatic carbon chain having 1-6 carbon atoms or is a substituted or unsubstituted phenylene group and R* is H, phenyl or alkyl having 1-6 carbon atoms.

10. (New) The conjugate according to claim 7, wherein said cytostatic compound having said spacer comprising a group which is derived from a maleinimido group, is formed through reaction of said cytostatic compound with a maleinimide compound of the formula V, VI or VII:

Formula V



Formula VI



Formula VII



wherein, R is an aliphatic carbon chain having 1-6 carbon atoms or a substituted or unsubstituted benzyl group or a substituted or unsubstituted phenylene group, Y = -OH, -COOH, -COCl, -CONH-$(CH_2)_n$-OH, -COO-$(CH_2)_n$-NH_2, -COO-$(CH_2)_n$-$NHNH_2$, -SO_3H, -

SO_3Cl, $-SO_2-NHNH_2$, -O-COCl, -CHO or -COR*, wherein n = 1-6 and R* represents H, phenyl or alkyl having 1-6 carbon atoms, and

the thus obtained maleinimide derivative of said cytostatic compound is coupled to said thiolated albumin or said thiolated transferrin or said polyethylene glycol, wherein the chemical linkage between said cytostatic compound and said maleinimide compound occurs through an amide, ester, imine, hydrazone, carboxyl hydrazone, oxycarbonyl, acetal or ketal bond.

11. (New) A method for the production of a conjugate of a cytostatic compound and transferrin or albumin or a polyethylene glycol according to claim 7, comprising the steps of:

(a) reacting a cytostatic compound with a maleinimide compound, such that maleinimide derivatives of said cytostatic compound are produced, wherein the chemical linkage between said cytostatic compound and said maleinimide compound occurs through an amide, ester, imine, hydrazone, carboxyl hydrazone, oxycarbonyl, acetal or ketal bond; and

(b) (i) coupling said maleinimide derivative obtained in step (a) of the cytostatic compound to thiolated transferrin or albumin having 1 to 30 HS groups on the average or to polyethylene glycol having at least one HS or H_2N group and having a mass of about between 5,000 and 200,000 Da; or

(ii) loading thiolated albumin with 2 to 30 equivalents of said maleinimide derivatives obtained in step (a) of the cytostatic compound and conjugating with transferrin or a monoclonal antibody directed to a tumor-associated antigen via a group which is derived from a bismaleinimido compound.

12. (New) A pharmaceutical composition, comprising the conjugate according to claim 7, optionally together with carriers and auxiliary agents.

13. (New) Method for the treatment of a cancer disease, comprising the step of treating an organism having a cancer disease with the conjugate of claim 7.

14. (New) Method according to claim 13, wherein said cancer disease comprises bladder, lung, mamma, melanoma or prostrate carcinomas.